Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Chart - target on ACLS...Currently up 18% and getting anxious to lock in my profits...However, I sold ATRC way too early today...Be greedy and hold ACLS for more, or bank my bucks and catch the next alert....TIA....You faithful follower...Aggie...
#8...BTW...This was my last pick...Too many lying a@@ CEO's and pumpsters...Aggie...
OCLS rocking PreMarket....PM High 4.35 (+.99cents)...Aggie...
FDA Clears Expanded Label Claim for Oculus Innovative Sciences' Lead Microcyn(R) Wound Care Product
8:08a ET June 4, 2009 (Business Wire)
Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a healthcare company that develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, today announced that it has received an expanded 510(k) label clearance from the U.S. Food and Drug Administration (FDA) to market its Microcyn(R) Skin and Wound Cleanser with preservatives as both a prescription and over-the-counter formulation. The new Rx product is indicated for use by health care professionals to manage the debridement of wounds such as stage I-IV pressure ulcers, diabetic foot ulcers, post-surgical wounds, first- and second-degree wounds, grafted and donor sites.
Microcyn(R) Skin and Wound Cleanser with preservative demonstrated rapid activity against a broad spectrum of gram-positive, gram-negative and yeast species with the following in vitro time kill method results in solution:
Name of Organism Time to Kill Percent Reduction MRSA - Staphylococcus aureus 30 seconds 99.9999% VRE - Enterococcus faecalis 30 seconds 99.9999% Staphylococcus aureus 30 seconds 99.9999% Escherichia coli 30 seconds 99.9997% Acinetobacter baumannii 30 seconds 99.9999% Bacteroides fragilis 30 seconds 99.9999% Candida albicans 30 seconds 99.9999% Enterobacter aerogenes 30 seconds 99.9999% Enterococcus faecium 30 seconds 99.9999% Haemophilus influenzae 30 seconds 99.9993% Klebsiella oxytoca 30 seconds 99.9999% Klebsiella pneumoniae 30 seconds 99.9999% Micrococcus luteus 30 seconds 99.9999% Proteus mirabilis 30 seconds 99.9999% Pseudomonas aeruginosa 30 seconds 99.9998% Serratia marcescens 30 seconds 99.9999% Staphylococcus epidermidis 30 seconds 99.9998% Staphylococcus haemolyticus 30 seconds 99.9999% Staphylococcus homins 30 seconds 99.9996% Staphylococcus saprophyticus 30 seconds 99.9999% Streptococcus pyogenes 30 seconds 99.9999%
"We believe these impressive kill times further validate the Microcyn Technology's unique and proprietary mode of action. At the same time, the Microcyn solution is safe as saline," said Hoji Alimi, founder and CEO of Oculus. "This safety profile in combination with the FDA-reviewed rapid kill times simply can't be equaled by silver-based products or even dated and toxic home remedies such as diluted bleach or Dakin's solution, which impede wound healing. This is scientific fact."
Last week, Oculus announced FDA clearance of a new Microcyn(R) Skin and Wound HydroGel, which is reimbursable by both Medicare and Medicaid. The original Microcyn-based solution, branded as Microcyn Wound Care in the United States, Microdacyn60(TM) in Mexico, Dermacyn(TM) Wound Care in Europe and China and Oxum in India, has treated over one million patients worldwide without a report of a single serious adverse effect.
Oculus, in partnership with its North American contract sales organization, Advocos, will market and sell the Microcyn(R) Skin and Wound Cleanser with preservative along with the Microcyn(R) Skin and Wound HydroGel to the North American medical community beginning in June 2009. Medical professionals interested in more information should contact Advocos at 678-213-0649 or email info@advocos.com.
There will be expanded discussion of these latest FDA clearances during the company's Q4 2009 earnings conference call at 1:30 p.m. PDT (4:30 p.m. ET) on Thursday, June 11, 2009. Individuals interested in participating in the conference call may do so by dialing 877-397-0292 for domestic callers or 719-325-4907 for international callers.
About Oculus
Oculus Innovative Sciences develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, which includes new formulations designed to significantly reduce the need for antibiotics as it reduces infections. The Microcyn Technology platform features a biocompatible, shelf-stable solution that is currently commercialized in the United States, Europe, India, China and Mexico and select Middle East countries. Several solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores, increase blood flow to the wound site, reduce both inflammation and pain while assisting in faster wound closure. The company's headquarters are in Petaluma, California, with operations in Europe and Latin America. More information can be found at www.oculusis.com.
Forward-Looking Statements
Except for historical information herein, some matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the company's commercial and technology progress. These forward-looking statements are identified by the use of words such as "validate," "will market," and "will be," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including risks inherent in the development and commercialization of potential products, the risk that regulatory clinical and guideline developments may change, the risk that scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, the risk that clinical results may not be replicated in actual patient settings, the risk that protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, the risk that present trends will continue and that the available market for our products will not be as large as expected, the risk that our products will not be able to penetrate one or more targeted markets, the risk that revenues will not be sufficient to fund further development and clinical studies, the Company's future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the quarterly report on Form 10-Q for the quarter ended December 31, 2008. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements
Oculus Innovative Sciences, Microdacyn60, Dermacyn and Microcyn Technology are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.
SOURCE: Oculus Innovative Sciences, Inc.
OCLS rocking PreMarket....PM High 4.35 (+.99cents)...Aggie...
FDA Clears Expanded Label Claim for Oculus Innovative Sciences' Lead Microcyn(R) Wound Care Product
8:08a ET June 4, 2009 (Business Wire)
Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a healthcare company that develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, today announced that it has received an expanded 510(k) label clearance from the U.S. Food and Drug Administration (FDA) to market its Microcyn(R) Skin and Wound Cleanser with preservatives as both a prescription and over-the-counter formulation. The new Rx product is indicated for use by health care professionals to manage the debridement of wounds such as stage I-IV pressure ulcers, diabetic foot ulcers, post-surgical wounds, first- and second-degree wounds, grafted and donor sites.
Microcyn(R) Skin and Wound Cleanser with preservative demonstrated rapid activity against a broad spectrum of gram-positive, gram-negative and yeast species with the following in vitro time kill method results in solution:
Name of Organism Time to Kill Percent Reduction MRSA - Staphylococcus aureus 30 seconds 99.9999% VRE - Enterococcus faecalis 30 seconds 99.9999% Staphylococcus aureus 30 seconds 99.9999% Escherichia coli 30 seconds 99.9997% Acinetobacter baumannii 30 seconds 99.9999% Bacteroides fragilis 30 seconds 99.9999% Candida albicans 30 seconds 99.9999% Enterobacter aerogenes 30 seconds 99.9999% Enterococcus faecium 30 seconds 99.9999% Haemophilus influenzae 30 seconds 99.9993% Klebsiella oxytoca 30 seconds 99.9999% Klebsiella pneumoniae 30 seconds 99.9999% Micrococcus luteus 30 seconds 99.9999% Proteus mirabilis 30 seconds 99.9999% Pseudomonas aeruginosa 30 seconds 99.9998% Serratia marcescens 30 seconds 99.9999% Staphylococcus epidermidis 30 seconds 99.9998% Staphylococcus haemolyticus 30 seconds 99.9999% Staphylococcus homins 30 seconds 99.9996% Staphylococcus saprophyticus 30 seconds 99.9999% Streptococcus pyogenes 30 seconds 99.9999%
"We believe these impressive kill times further validate the Microcyn Technology's unique and proprietary mode of action. At the same time, the Microcyn solution is safe as saline," said Hoji Alimi, founder and CEO of Oculus. "This safety profile in combination with the FDA-reviewed rapid kill times simply can't be equaled by silver-based products or even dated and toxic home remedies such as diluted bleach or Dakin's solution, which impede wound healing. This is scientific fact."
Last week, Oculus announced FDA clearance of a new Microcyn(R) Skin and Wound HydroGel, which is reimbursable by both Medicare and Medicaid. The original Microcyn-based solution, branded as Microcyn Wound Care in the United States, Microdacyn60(TM) in Mexico, Dermacyn(TM) Wound Care in Europe and China and Oxum in India, has treated over one million patients worldwide without a report of a single serious adverse effect.
Oculus, in partnership with its North American contract sales organization, Advocos, will market and sell the Microcyn(R) Skin and Wound Cleanser with preservative along with the Microcyn(R) Skin and Wound HydroGel to the North American medical community beginning in June 2009. Medical professionals interested in more information should contact Advocos at 678-213-0649 or email info@advocos.com.
There will be expanded discussion of these latest FDA clearances during the company's Q4 2009 earnings conference call at 1:30 p.m. PDT (4:30 p.m. ET) on Thursday, June 11, 2009. Individuals interested in participating in the conference call may do so by dialing 877-397-0292 for domestic callers or 719-325-4907 for international callers.
About Oculus
Oculus Innovative Sciences develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, which includes new formulations designed to significantly reduce the need for antibiotics as it reduces infections. The Microcyn Technology platform features a biocompatible, shelf-stable solution that is currently commercialized in the United States, Europe, India, China and Mexico and select Middle East countries. Several solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores, increase blood flow to the wound site, reduce both inflammation and pain while assisting in faster wound closure. The company's headquarters are in Petaluma, California, with operations in Europe and Latin America. More information can be found at www.oculusis.com.
Forward-Looking Statements
Except for historical information herein, some matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the company's commercial and technology progress. These forward-looking statements are identified by the use of words such as "validate," "will market," and "will be," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including risks inherent in the development and commercialization of potential products, the risk that regulatory clinical and guideline developments may change, the risk that scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, the risk that clinical results may not be replicated in actual patient settings, the risk that protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, the risk that present trends will continue and that the available market for our products will not be as large as expected, the risk that our products will not be able to penetrate one or more targeted markets, the risk that revenues will not be sufficient to fund further development and clinical studies, the Company's future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the quarterly report on Form 10-Q for the quarter ended December 31, 2008. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements
Oculus Innovative Sciences, Microdacyn60, Dermacyn and Microcyn Technology are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.
SOURCE: Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences, Inc. Media and Investor Contact: Director of Public and Investor Relations Dan McFadden, 425-753-2105 dmcfadden@oculusis.com
WOW!!! TELK exploding +97%...Sold too soon!!!! Aggie...
Out of TELK @ 1.04 from .75 entry....
TELK +40%
TELK + 29%
BEXP as high as 3.92 PM.
HGSI as high as 2.94 PM.
CRGN as high as 1.90 PM.
DPTR as high as 2.18 PM.
HGSI rocking....
Sheff,
What is your target with CRGN....Missed the boat @ 1.20 and dont want to chase...TIA..Aggie...
I also believe I have read of a possible short of this one. Coupled that with the small float....Aggie...
Took 1K of these also @ 3.66 at close...Aggie...
In with you again....Price target??? I seem to be getting out to early...Guess that is better than too late LOL...Aggie..
Nice...Just had a moment to check the day...Very pleasantly suprised...Think I am going to lock in my profits here...Waiting for your next call...Aggie...
Joined you @ 3.04...You seem to be on a roll lately....Aggie....
Out 4.65 from 3.86 & 3.09....Great pick Geaux......aggie...
Shaping up to be a good day for us on ZLC!!! Aggie...
Thanks for the updates Ken....I only watch the Wealth University board and do appreciate updates on the stockseasonality picks on this board...IMO....Aggie
Doubled down with you at 3.09.....about 3.45 avg now....Aggie...
I sold yesterday at 1.90 from 1.51 entry. Got back in just now at 1.44. Remember to take your profits when available...Aggie...
Joined you on a little ZLC again @ 3.86 Mr. Geaux...Played this one last week also...I think this is the 4th time this month I have played one of your picks....All Profitable thusfar I might add...Mucho Gracias...Aggie...
KFN now 1.92
AXL - Wow!!! up 103% for day....
KFN 1.98 PM
MPG 1.70 PM
CT 2.10 PM
VG in @ .84 PM
Shaping up to be another great day.....Aggie...
Love those new "starburst" rated stocks Chart/Ken...Picked up MTL on Monday for nice profit and HW today (3.80 to 4.20)...Also following your lead on all the university alerts...This site has been a life changer for me...Aggie...
XTXI - Old WU pick from Jan...Exploded today up 1.47/share to 3.68 (+66.52%)...Aggie...
Joined you 4.02 on this on also....Do you have a target in mind? Aggie....
Joined you in a little CZZ....Aggie...
Glassy,
Notice you are from Texas. What part of the great state are you from?
Aggie...
PRXI - .95
Premier Exhibitions Clarifies Offers Made by G. Michael Harris 04/15 03:04 PM
ATLANTA, April 15, 2009 (GLOBE NEWSWIRE) -- Premier Exhibitions, Inc. (PRXI:$0.90,00$0.1201,15.40%) announced today that its board of directors is reviewing the offers made by G. Michael Harris to Premier and Sellers Capital LLC. Premier also clarified that the offers made by Harris are not an offer to acquire Premier or its wholly-owned subsidiary R.M.S. Titanic, Inc.
Harris has offered to acquire the 4,778,399 shares of Premier held by Sellers Capital LLC, which represents approximately 16.3% of Premier's outstanding shares, for a purchase price equal to $3.00 per share. Harris' offer is subject to a 45-day due diligence period, which would follow the execution of definitive documents. Harris has also requested three board seats and control of all executive positions of Premier. Although the offer has been made to Sellers Capital LLC, only Premier's board of directors could agree to the extraordinary step of making board seats or executive positions available to an outside party.
Harris also has provided Premier with a preliminary outline of terms under which Harris would acquire the exclusive rights to manage the Titanic assets possessed by Premier's wholly owned subsidiary R.M.S. Titanic, Inc. for a period of five years, pursuant to which Harris proposes to pay Premier $5.0 million per year plus an unspecified percentage of all merchandise, touring and television revenues and Harris would receive one million shares of Premier plus an unspecified number of stock options. This offer is also subject to a 45-day due diligence period, which would follow the execution of definitive documents.
Harris has not indicated to Premier how these offers would be financed. Premier's board of directors is undertaking an appropriate review of Harris' offers and will respond to Mr. Harris when its review is completed.
Forward-Looking Statements
Certain of the statements contained in this press release contain forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Premier has based these forward-looking statements on its current expectations and projections about future events, based on the information currently available to it. The forward-looking statements contained in this press release may also include statements relating to Premier's anticipated financial performance, business prospects, new developments, strategies and similar matters. Certain of the factors described in Premier's filings with the Securities and Exchange Commission, including the section of its Annual Report on Form 10-K for the year ended February 29, 2008 titled "Risk Factors," may affect Premier's future results and cause those results to differ materially from those expressed in the forward-looking statements. Premier disclaims any obligation to update any of its forward-looking statements, except as may be required by law.
CONTACT: Premier Exhibitions, Inc. (PRXI:$0.90,00$0.1201,15.40%)
Investor Relations:
404-842-2600
Media Inquiries:
Katherine Morgenstern
(404) 842-2600
kmorgenstern@prxi.com
Get more news on:SYMBOLS: PRXI
PRXI - .95
Premier Exhibitions Clarifies Offers Made by G. Michael Harris 04/15 03:04 PM
ATLANTA, April 15, 2009 (GLOBE NEWSWIRE) -- Premier Exhibitions, Inc. (PRXI:$0.90,00$0.1201,15.40%) announced today that its board of directors is reviewing the offers made by G. Michael Harris to Premier and Sellers Capital LLC. Premier also clarified that the offers made by Harris are not an offer to acquire Premier or its wholly-owned subsidiary R.M.S. Titanic, Inc.
Harris has offered to acquire the 4,778,399 shares of Premier held by Sellers Capital LLC, which represents approximately 16.3% of Premier's outstanding shares, for a purchase price equal to $3.00 per share. Harris' offer is subject to a 45-day due diligence period, which would follow the execution of definitive documents. Harris has also requested three board seats and control of all executive positions of Premier. Although the offer has been made to Sellers Capital LLC, only Premier's board of directors could agree to the extraordinary step of making board seats or executive positions available to an outside party.
Harris also has provided Premier with a preliminary outline of terms under which Harris would acquire the exclusive rights to manage the Titanic assets possessed by Premier's wholly owned subsidiary R.M.S. Titanic, Inc. for a period of five years, pursuant to which Harris proposes to pay Premier $5.0 million per year plus an unspecified percentage of all merchandise, touring and television revenues and Harris would receive one million shares of Premier plus an unspecified number of stock options. This offer is also subject to a 45-day due diligence period, which would follow the execution of definitive documents.
Harris has not indicated to Premier how these offers would be financed. Premier's board of directors is undertaking an appropriate review of Harris' offers and will respond to Mr. Harris when its review is completed.
Forward-Looking Statements
Certain of the statements contained in this press release contain forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Premier has based these forward-looking statements on its current expectations and projections about future events, based on the information currently available to it. The forward-looking statements contained in this press release may also include statements relating to Premier's anticipated financial performance, business prospects, new developments, strategies and similar matters. Certain of the factors described in Premier's filings with the Securities and Exchange Commission, including the section of its Annual Report on Form 10-K for the year ended February 29, 2008 titled "Risk Factors," may affect Premier's future results and cause those results to differ materially from those expressed in the forward-looking statements. Premier disclaims any obligation to update any of its forward-looking statements, except as may be required by law.
CONTACT: Premier Exhibitions, Inc. (PRXI:$0.90,00$0.1201,15.40%)
Investor Relations:
404-842-2600
Media Inquiries:
Katherine Morgenstern
(404) 842-2600
kmorgenstern@prxi.com
Get more news on:SYMBOLS: PRXI
Wow!!! ditto, I exited at 3.00....
Just faithfully following the leader!!!! Aggie...
Out CROX @ 2.22 from 2.06 entry.
Out XOMA @.4511 for small loss
Out CMRG @ .70 from .60 entry.
Still holding a little FIG, TWB and CNTF....Aggie....
CROX HOD...Anyone beside me still holding some? Aggie...
Congrats on the Blazers win last night. Roy was on fire. Even though my team came out on the wrong side of the scoreboard, it was one of the most intertaining games of the year. Someone else from Portland has got to step up, cannot expect Roy to score 42 every night....Aggie...
Hmmm! Back to a penny...Watching closely for reload point...Aggie.....
Rockets die hard here...I expect them to do well this year.... Artest gives them the toughness they have lacked in the past...Brooks give them quickness and a play maker...Landry is an up and comer...Ming is 7'6" and has skills...McGrady was nothing but a pu$$ who could never hit a shot when in counted...My bet is Rockets in 6...Aggie...
No hard feeling $heff, but my rockets are gonna kick Portland's butt...I still like you though...HaHa...Aggie...